Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Magenta Therapeutics reports Q1 EPS (36c), consensus (40c) » 08:24
05/06/21
05/06
08:24
05/06/21
08:24
MGTA

Magenta Therapeutics

$11.35 /

-0.07 (-0.61%)

Magenta Therapeutics…

Magenta Therapeutics reported financial results for the first quarter ended March 31, 2021 and recent program highlights. "Magenta continues to make progress across our program portfolio, building momentum towards several key anticipated clinical and data milestones throughout 2021, including the initial Phase 2 trial results evaluating MGTA-145 plus plerixafor in Multiple Myeloma patients in an autologous transplant setting and filing an IND for first-in-human Phase 1/2 clinical trial of MGTA-117, our first product candidate from our targeted conditioning platform," said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. "We are optimistic about our programs' ability to transform clinical practice of stem cell transplants and gene therapies with new first-line medicines, which we believe could increase access to curative transplants across multiple disease areas."

ShowHide Related Items >><<
MGTA Magenta Therapeutics
$11.35 /

-0.07 (-0.61%)

MGTA Magenta Therapeutics
$11.35 /

-0.07 (-0.61%)

01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Mizuho
Mizuho starts 'under the radar' Magenta with Buy, $16 target
01/06/21 Mizuho
Magenta Therapeutics initiated with a Buy at Mizuho
10/14/20 JPMorgan
Magenta Therapeutics resumed with an Overweight at JPMorgan
MGTA Magenta Therapeutics
$11.35 /

-0.07 (-0.61%)

  • 25
    Jun
Over a week ago
Conference/Events
Magenta Therapeutics participates in a conference call with JPMorgan » 09:35
04/28/21
04/28
09:35
04/28/21
09:35
MGTA

Magenta Therapeutics

$11.49 /

+0.18 (+1.59%)

Conference call with CEO…

Conference call with CEO Gardner will be held on April 28 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
MGTA Magenta Therapeutics
$11.49 /

+0.18 (+1.59%)

MGTA Magenta Therapeutics
$11.49 /

+0.18 (+1.59%)

01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Mizuho
Mizuho starts 'under the radar' Magenta with Buy, $16 target
01/06/21 Mizuho
Magenta Therapeutics initiated with a Buy at Mizuho
10/14/20 JPMorgan
Magenta Therapeutics resumed with an Overweight at JPMorgan
MGTA Magenta Therapeutics
$11.49 /

+0.18 (+1.59%)

  • 25
    Jun
Hot Stocks
Magenta Therapeutics appoints David Nichols as CTO » 08:04
04/19/21
04/19
08:04
04/19/21
08:04
MGTA

Magenta Therapeutics

$11.01 /

+0.22 (+2.04%)

, KNSA

Kiniksa

$15.61 /

-0.79 (-4.82%)

Magenta Therapeutics…

Magenta Therapeutics (MGTA) announced the appointment of David Nichols as CTO. As chief technical officer, Nichols will serve as a member of the company's executive team and will lead all of Magenta's CMC activities from early development through commercial products across the company's pipeline, including driving strategic initiatives to improve efficiency, consistency, compliance and risk mitigation for Magenta's antibody drug conjugate, cell therapy, and peptide manufacturing processes. Nichols comes to Magenta with more than 25 years of experience in biologics process development across the life sciences industry. Most recently, Nichols served as senior VP of Kiniksa (KNSA) where he was responsible for all process development and internal and external GMP manufacturing.

ShowHide Related Items >><<
MGTA Magenta Therapeutics
$11.01 /

+0.22 (+2.04%)

KNSA Kiniksa
$15.61 /

-0.79 (-4.82%)

MGTA Magenta Therapeutics
$11.01 /

+0.22 (+2.04%)

01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Mizuho
Mizuho starts 'under the radar' Magenta with Buy, $16 target
01/06/21 Mizuho
Magenta Therapeutics initiated with a Buy at Mizuho
10/14/20 JPMorgan
Magenta Therapeutics resumed with an Overweight at JPMorgan
KNSA Kiniksa
$15.61 /

-0.79 (-4.82%)

03/18/21 Evercore ISI
Kiniksa sNDA looks to be approved by FDA, says Evercore ISI
11/24/20 Evercore ISI
Kiniksa initiated with an Outperform at Evercore ISI
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
07/17/20 JPMorgan
Kiniksa risk/reward attractive into Phase 2 data, says JPMorgan
MGTA Magenta Therapeutics
$11.01 /

+0.22 (+2.04%)

KNSA Kiniksa
$15.61 /

-0.79 (-4.82%)

  • 22
    Jul
  • 25
    Jun
  • 14
    May
KNSA Kiniksa
$15.61 /

-0.79 (-4.82%)

Conference/Events
Magenta Therapeutics management to meet virtually with Mizuho » 04:55
04/16/21
04/16
04:55
04/16/21
04:55
MGTA

Magenta Therapeutics

$10.77 /

-0.2 (-1.82%)

Virtual Meetings to be…

Virtual Meetings to be held on April 15-16 hosted by Mizuho.

ShowHide Related Items >><<
MGTA Magenta Therapeutics
$10.77 /

-0.2 (-1.82%)

MGTA Magenta Therapeutics
$10.77 /

-0.2 (-1.82%)

01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Mizuho
Mizuho starts 'under the radar' Magenta with Buy, $16 target
01/06/21 Mizuho
Magenta Therapeutics initiated with a Buy at Mizuho
10/14/20 JPMorgan
Magenta Therapeutics resumed with an Overweight at JPMorgan
MGTA Magenta Therapeutics
$10.77 /

-0.2 (-1.82%)

  • 25
    Jun
Conference/Events
Magenta Therapeutics management to meet virtually with Mizuho » 04:55
04/15/21
04/15
04:55
04/15/21
04:55
MGTA

Magenta Therapeutics

$10.97 /

+0.28 (+2.62%)

Virtual Meetings to be…

Virtual Meetings to be held on April 15-16 hosted by Mizuho.

ShowHide Related Items >><<
MGTA Magenta Therapeutics
$10.97 /

+0.28 (+2.62%)

MGTA Magenta Therapeutics
$10.97 /

+0.28 (+2.62%)

01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Mizuho
Mizuho starts 'under the radar' Magenta with Buy, $16 target
01/06/21 Mizuho
Magenta Therapeutics initiated with a Buy at Mizuho
10/14/20 JPMorgan
Magenta Therapeutics resumed with an Overweight at JPMorgan
MGTA Magenta Therapeutics
$10.97 /

+0.28 (+2.62%)

  • 25
    Jun
Conference/Events
Magenta Therapeutics management to meet virtually with Mizuho » 10:37
04/14/21
04/14
10:37
04/14/21
10:37
MGTA

Magenta Therapeutics

$11.28 /

+0.59 (+5.52%)

Virtual Meetings to be…

Virtual Meetings to be held on April 15-16 hosted by Mizuho.

ShowHide Related Items >><<
MGTA Magenta Therapeutics
$11.28 /

+0.59 (+5.52%)

MGTA Magenta Therapeutics
$11.28 /

+0.59 (+5.52%)

01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Mizuho
Mizuho starts 'under the radar' Magenta with Buy, $16 target
01/06/21 Mizuho
Magenta Therapeutics initiated with a Buy at Mizuho
10/14/20 JPMorgan
Magenta Therapeutics resumed with an Overweight at JPMorgan
MGTA Magenta Therapeutics
$11.28 /

+0.59 (+5.52%)

  • 25
    Jun
Over a month ago
Conference/Events
Guggenheim to hold a virtual conference » 09:47
04/01/21
04/01
09:47
04/01/21
09:47
CATB

Catabasis Pharmaceuticals

$2.89 /

+ (+0.00%)

, ORPH

Orphazyme

$8.40 /

-0.08 (-0.94%)

, FIXX

Homology Medicines

$9.50 /

+0.09 (+0.96%)

, MGTA

Magenta Therapeutics

$12.24 /

+0.45 (+3.82%)

, PASG

Passage Bio

$17.55 /

+ (+0.00%)

, PFE

Pfizer

$36.17 /

-0.07 (-0.19%)

, RARE

Ultragenyx

$114.03 /

+ (+0.00%)

, RNA

Avidity Biosciences

$22.20 /

+0.37 (+1.69%)

, SGMO

Sangamo

$12.65 /

+0.115 (+0.92%)

, SIOX

Sio Gene Therapies

$2.64 /

+0.025 (+0.96%)

, SLDB

Solid Biosciences

$5.54 /

-0.01 (-0.18%)

, SRPT

Sarepta

$75.45 /

+0.84 (+1.13%)

, ZEAL

Zealand Pharma

$31.11 /

+ (+0.00%)

Healthcare Talks: Genomic…

Healthcare Talks: Genomic Medicines & Rare Diseases Virtual Conference 2021 will be held on April 1.

ShowHide Related Items >><<
ZEAL Zealand Pharma
$31.11 /

+ (+0.00%)

SRPT Sarepta
$75.45 /

+0.84 (+1.13%)

SLDB Solid Biosciences
$5.54 /

-0.01 (-0.18%)

SIOX Sio Gene Therapies
$2.64 /

+0.025 (+0.96%)

SGMO Sangamo
$12.65 /

+0.115 (+0.92%)

RNA Avidity Biosciences
$22.20 /

+0.37 (+1.69%)

RARE Ultragenyx
$114.03 /

+ (+0.00%)

PFE Pfizer
$36.17 /

-0.07 (-0.19%)

PASG Passage Bio
$17.55 /

+ (+0.00%)

ORPH Orphazyme
$8.40 /

-0.08 (-0.94%)

MGTA Magenta Therapeutics
$12.24 /

+0.45 (+3.82%)

FIXX Homology Medicines
$9.50 /

+0.09 (+0.96%)

CATB Catabasis Pharmaceuticals
$2.89 /

+ (+0.00%)

CATB Catabasis Pharmaceuticals
$2.89 /

+ (+0.00%)

03/11/21 Oppenheimer
Catabasis Pharmaceuticals upgraded to Outperform at Oppenheimer
03/11/21 Oppenheimer
Catabasis upgraded to Outperform from Perform at Oppenheimer
11/02/20 Wedbush
Catabasis Pharmaceuticals downgraded to Neutral at Wedbush
11/02/20 Wedbush
Catabasis Pharmaceuticals downgraded to Neutral from Outperform at Wedbush
ORPH Orphazyme
$8.40 /

-0.08 (-0.94%)

03/30/21 BofA
Orphazyme downgraded to Underperform from Neutral at BofA
03/30/21 BofA
Orphazyme downgraded to Underperform from Neutral at BofA
10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
FIXX Homology Medicines
$9.50 /

+0.09 (+0.96%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
MGTA Magenta Therapeutics
$12.24 /

+0.45 (+3.82%)

01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Mizuho
Mizuho starts 'under the radar' Magenta with Buy, $16 target
01/06/21 Mizuho
Magenta Therapeutics initiated with a Buy at Mizuho
10/14/20 JPMorgan
Magenta Therapeutics resumed with an Overweight at JPMorgan
PASG Passage Bio
$17.55 /

+ (+0.00%)

03/08/21 Chardan
Passage Bio price target raised to $45 from $35 at Chardan
03/04/21 Citi
Citi remains buyer of Passage Bio into first clinical data
03/04/21 Goldman Sachs
Passage Bio upgraded to Buy from Neutral at Goldman Sachs
02/04/21
Fly Intel: Top five analyst initiations
PFE Pfizer
$36.17 /

-0.07 (-0.19%)

03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
RARE Ultragenyx
$114.03 /

+ (+0.00%)

03/24/21 Stifel
Stifel remains optimistic on GTX-102 and Ultragenyx ahead of 'important' update
03/01/21 Stifel
Ultragenyx resumed with a Buy at Stifel
02/12/21 Wedbush
Ultragenyx price target raised to $130 from $113 at Wedbush
02/12/21 Barclays
Ultragenyx price target raised to $186 from $176 at Barclays
RNA Avidity Biosciences
$22.20 /

+0.37 (+1.69%)

07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 SVB Leerink
Avidity Biosciences initiated with an Outperform at SVB Leerink
07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 Wells Fargo
Avidity Biosciences initiated with an Overweight at Wells Fargo
SGMO Sangamo
$12.65 /

+0.115 (+0.92%)

03/03/21 Wells Fargo
Sangamo price target lowered to $29 from $36 at Wells Fargo
01/05/21 Stifel
Sangamo initiated with a Hold at Stifel
12/16/20 H.C. Wainwright
Sangamo assumed with a Buy at H.C. Wainwright
09/08/20 BofA
Sangamo resumed with a Buy at BofA
SIOX Sio Gene Therapies
$2.64 /

+0.025 (+0.96%)

SLDB Solid Biosciences
$5.54 /

-0.01 (-0.18%)

03/16/21 Chardan
Solid Biosciences price target raised to $20 from $12.50 at Chardan
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform at SVB Leerink
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink
SRPT Sarepta
$75.45 /

+0.84 (+1.13%)

03/02/21 RBC Capital
Sarepta price target lowered to $132 from $143 at RBC Capital
03/02/21 Piper Sandler
Sarepta price target lowered to $130 from $140 at Piper Sandler
02/26/21 Mizuho
Sarepta price target raised to $160 from $158 at Mizuho
02/25/21 Piper Sandler
Piper says Sarepta's Amondys 45 approval comes with 'relatively clean label'
ZEAL Zealand Pharma
$31.11 /

+ (+0.00%)

ZEAL Zealand Pharma
$31.11 /

+ (+0.00%)

SRPT Sarepta
$75.45 /

+0.84 (+1.13%)

SLDB Solid Biosciences
$5.54 /

-0.01 (-0.18%)

SIOX Sio Gene Therapies
$2.64 /

+0.025 (+0.96%)

SGMO Sangamo
$12.65 /

+0.115 (+0.92%)

RNA Avidity Biosciences
$22.20 /

+0.37 (+1.69%)

RARE Ultragenyx
$114.03 /

+ (+0.00%)

PFE Pfizer
$36.17 /

-0.07 (-0.19%)

PASG Passage Bio
$17.55 /

+ (+0.00%)

MGTA Magenta Therapeutics
$12.24 /

+0.45 (+3.82%)

FIXX Homology Medicines
$9.50 /

+0.09 (+0.96%)

CATB Catabasis Pharmaceuticals
$2.89 /

+ (+0.00%)

  • 19
    Mar
  • 22
    Jan
  • 29
    Oct
  • 29
    Sep
  • 25
    Jun
  • 12
    Jun
PFE Pfizer
$36.17 /

-0.07 (-0.19%)

SRPT Sarepta
$75.45 /

+0.84 (+1.13%)

SLDB Solid Biosciences
$5.54 /

-0.01 (-0.18%)

SIOX Sio Gene Therapies
$2.64 /

+0.025 (+0.96%)

PFE Pfizer
$36.17 /

-0.07 (-0.19%)

PASG Passage Bio
$17.55 /

+ (+0.00%)

ORPH Orphazyme
$8.40 /

-0.08 (-0.94%)

FIXX Homology Medicines
$9.50 /

+0.09 (+0.96%)

CATB Catabasis Pharmaceuticals
$2.89 /

+ (+0.00%)

SIOX Sio Gene Therapies
$2.64 /

+0.025 (+0.96%)

SGMO Sangamo
$12.65 /

+0.115 (+0.92%)

PFE Pfizer
$36.17 /

-0.07 (-0.19%)

PASG Passage Bio
$17.55 /

+ (+0.00%)

CATB Catabasis Pharmaceuticals
$2.89 /

+ (+0.00%)

Earnings
Magenta Therapeutics reports Q4 EPS (38c), consensus (41c) » 08:05
03/03/21
03/03
08:05
03/03/21
08:05
MGTA

Magenta Therapeutics

$11.84 /

+0.79 (+7.15%)

Cash Position: Cash, cash…

Cash Position: Cash, cash equivalents and marketable securities as of December 31, 2020, were $148.8M, compared to $145.7M as of December 31, 2019. Magenta anticipates that its cash, cash equivalents and marketable securities will be sufficient to fund operations and capital expenditures into 2023."Building on our momentum from 2020, we continue to advance our portfolio with now two active Phase 2 clinical trials evaluating MGTA-145 plus plerixafor in patients with blood cancers undergoing autologous and allogeneic stem cell transplant and an additional planned Phase 2 clinical trial evaluating stem cell mobilization and collection in patients with sickle cell disease in partnership with bluebird bio. We have also made additional progress in our preparations for an IND filing for our MGTA-117 targeted conditioning program based on communications with the FDA and the advancement of our IND-enabling studies," said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. "We very much look forward to generating clinical data during the course of 2021 in these multiple disease settings."

ShowHide Related Items >><<
MGTA Magenta Therapeutics
$11.84 /

+0.79 (+7.15%)

MGTA Magenta Therapeutics
$11.84 /

+0.79 (+7.15%)

01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Mizuho
Mizuho starts 'under the radar' Magenta with Buy, $16 target
01/06/21 Mizuho
Magenta Therapeutics initiated with a Buy at Mizuho
10/14/20 JPMorgan
Magenta Therapeutics resumed with an Overweight at JPMorgan
MGTA Magenta Therapeutics
$11.84 /

+0.79 (+7.15%)

  • 25
    Jun
Over a quarter ago
Initiation
Fly Intel: Top five analyst initiations » 09:56
01/07/21
01/07
09:56
01/07/21
09:56
ARCT

Arcturus Therapeutics

$52.26 /

+2.9 (+5.88%)

, MGTA

Magenta Therapeutics

$8.24 /

+0.34 (+4.30%)

, ARAY

Accuray

$4.95 /

+0.08 (+1.64%)

, NOG

Northern Oil and Gas

$9.89 /

+0.26 (+2.70%)

, KNOP

Knot Offshore Partners

$15.55 /

+0.26 (+1.70%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Arcturus Therapeutics (ARCT) initiated with an Overweight at Wells Fargo. 2. Magenta Therapeutics (MGTA) initiated with a Buy at Mizuho. 3. Accuray (ARAY) initiated with an Outperform at Northland. 4. Northern Oil and Gas (NOG) initiated with a Strong Buy at Raymond James. 5. Knot Offshore Partners (KNOP) initiated with Buy at B. Riley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
NOG Northern Oil and Gas
$9.89 /

+0.26 (+2.70%)

MGTA Magenta Therapeutics
$8.24 /

+0.34 (+4.30%)

KNOP Knot Offshore Partners
$15.55 /

+0.26 (+1.70%)

ARCT Arcturus Therapeutics
$52.26 /

+2.9 (+5.88%)

ARAY Accuray
$4.95 /

+0.08 (+1.64%)

ARCT Arcturus Therapeutics
$52.26 /

+2.9 (+5.88%)

01/07/21 Wells Fargo
Arcturus Therapeutics initiated with an Overweight at Wells Fargo
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
12/30/20 Piper Sandler
Piper says market 'overreacting' to Arcturus COVID data, sees value in platform
12/29/20
Fly Intel: Top five analyst calls
MGTA Magenta Therapeutics
$8.24 /

+0.34 (+4.30%)

01/07/21 Mizuho
Mizuho starts 'under the radar' Magenta with Buy, $16 target
01/06/21 Mizuho
Magenta Therapeutics initiated with a Buy at Mizuho
10/14/20 JPMorgan
Magenta Therapeutics resumed with an Overweight at JPMorgan
06/08/20 Goldman Sachs
Magenta Therapeutics upgraded to Buy from Neutral at Goldman Sachs
ARAY Accuray
$4.95 /

+0.08 (+1.64%)

01/07/21 Northland
Accuray initiated with an Outperform at Northland
09/28/20 Lake Street
CMS 'pouring fuel on the fire' for Accuray with APM rule, says Lake Street
09/18/20 Cowen
New CMS model should provide tailwind for Accuray, says Cowen
04/17/20 JPMorgan
Varian Medical price target lowered to $90 from $100 at JPMorgan
NOG Northern Oil and Gas
$9.89 /

+0.26 (+2.70%)

01/07/21 Raymond James
Northern Oil and Gas initiated with a Strong Buy at Raymond James
01/07/21 Raymond James
Northern Oil and Gas initiated with a Strong Buy at Raymond James
12/31/20 Truist
Northern Oil and Gas price target raised to $11 from $7 at Truist
10/15/20 Truist
Northern Oil and Gas price target lowered to $10 from $20 at Truist
KNOP Knot Offshore Partners
$15.55 /

+0.26 (+1.70%)

01/07/21 B. Riley
Knot Offshore Partners initiated with Buy, $20 target at B. Riley
01/06/21 B. Riley
KNOT Offshore Partners initiated with a Buy at B. Riley Securities
NOG Northern Oil and Gas
$9.89 /

+0.26 (+2.70%)

MGTA Magenta Therapeutics
$8.24 /

+0.34 (+4.30%)

ARCT Arcturus Therapeutics
$52.26 /

+2.9 (+5.88%)

ARAY Accuray
$4.95 /

+0.08 (+1.64%)

  • 08
    Dec
  • 29
    Jul
  • 25
    Jun
  • 16
    Apr
ARCT Arcturus Therapeutics
$52.26 /

+2.9 (+5.88%)

NOG Northern Oil and Gas
$9.89 /

+0.26 (+2.70%)

ARCT Arcturus Therapeutics
$52.26 /

+2.9 (+5.88%)

ARAY Accuray
$4.95 /

+0.08 (+1.64%)

ARCT Arcturus Therapeutics
$52.26 /

+2.9 (+5.88%)

Initiation
Mizuho starts 'under the radar' Magenta with Buy, $16 target » 06:54
01/07/21
01/07
06:54
01/07/21
06:54
MGTA

Magenta Therapeutics

$7.90 /

+0.16 (+2.07%)

Mizuho analyst Difei Yang…

Mizuho analyst Difei Yang last night initiated coverage of Magenta Therapeutics with a Buy rating and $16 price target. Magenta is developing a suite of novel medicines with the potential to change the standard of care for stem cell transplantation procedures across oncology and genetic diseases, Yang tells investors in a research note. The analyst is bullish on the shares ahead of initial Phase 1/2 data expected in 2021 based on "encouraging" early data in healthy volunteers and animal models. Yang sees Magenta as a "unique company currently under the radar."

ShowHide Related Items >><<
MGTA Magenta Therapeutics
$7.90 /

+0.16 (+2.07%)

MGTA Magenta Therapeutics
$7.90 /

+0.16 (+2.07%)

01/06/21 Mizuho
Magenta Therapeutics initiated with a Buy at Mizuho
10/14/20 JPMorgan
Magenta Therapeutics resumed with an Overweight at JPMorgan
06/08/20 Goldman Sachs
Magenta Therapeutics upgraded to Buy from Neutral at Goldman Sachs
01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
MGTA Magenta Therapeutics
$7.90 /

+0.16 (+2.07%)

  • 25
    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.